SECONDARY HYPERPARATHYROIDISM (SHPT) IN SUBJECTS WITH CHRONIC KIDNEY DISEASE (CKD) ON HEMODIALYSIS
Clinical trials for SECONDARY HYPERPARATHYROIDISM (SHPT) IN SUBJECTS WITH CHRONIC KIDNEY DISEASE (CKD) ON HEMODIALYSIS explained in plain language.
Never miss a new study
Get alerted when new SECONDARY HYPERPARATHYROIDISM (SHPT) IN SUBJECTS WITH CHRONIC KIDNEY DISEASE (CKD) ON HEMODIALYSIS trials appear
Sign up with your email to follow new studies for SECONDARY HYPERPARATHYROIDISM (SHPT) IN SUBJECTS WITH CHRONIC KIDNEY DISEASE (CKD) ON HEMODIALYSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New injection shows promise for dialysis patients with hormone imbalance
Disease control CompletedThis study tested a new drug called MT1013 in 115 adults with chronic kidney disease who are on dialysis and have a condition called secondary hyperparathyroidism (high parathyroid hormone). The goal was to see if the drug could safely lower hormone levels by at least 30%. Partic…
Matched conditions: SECONDARY HYPERPARATHYROIDISM (SHPT) IN SUBJECTS WITH CHRONIC KIDNEY DISEASE (CKD) ON HEMODIALYSIS
Phase: PHASE2 • Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New injection aims to tame hormone chaos in kidney dialysis patients
Disease control CompletedThis study tests a new drug called SHR6508 in 303 adults on hemodialysis who have secondary hyperparathyroidism, a condition where parathyroid hormone levels get too high. The drug is given as an injection to help control these hormone levels and related minerals like calcium and…
Matched conditions: SECONDARY HYPERPARATHYROIDISM (SHPT) IN SUBJECTS WITH CHRONIC KIDNEY DISEASE (CKD) ON HEMODIALYSIS
Phase: PHASE2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug shows promise for dialysis patients with hormone disorder
Disease control CompletedThis study tested a new drug called MT1013 in 98 adults on kidney dialysis who have secondary hyperparathyroidism, a condition where parathyroid hormone levels are too high. The goal was to see if the drug is safe and can lower these hormone levels. Participants received either t…
Matched conditions: SECONDARY HYPERPARATHYROIDISM (SHPT) IN SUBJECTS WITH CHRONIC KIDNEY DISEASE (CKD) ON HEMODIALYSIS
Phase: PHASE2 • Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC